Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Contract Win

9th Dec 2022 09:05

RNS Number : 2057J
IXICO plc
09 December 2022
 
9 December 2022

IXICO plc

("IXICO" or the "Company")

 

Contract win for an early phase Multiple System Atrophy disease trial

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that it has been selected by a leading global pharmaceutical company, and new client, to provide MRI imaging services for an early phase clinical trial in Multiple System Atrophy. IXICO has signed a start-up agreement with the client which is anticipated to extend to a contract value of approximately £0.6m early in 2023. The trial is expected to last for two years.

 

Since its inception, IXICO has built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders across the entire drug development lifecycle, from phase I through to commercialisation.

 

 

For further information please contact:

 

IXICO plc

+44 (0)20 3763 7499

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

 

 

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTUKRKRUUUURRA

Related Shares:

Ixico
FTSE 100 Latest
Value8,809.74
Change53.53